Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303377 | 0.91 | MAPT (0.52) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL25209624 | 0.85 | GPR119 (0.45) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL1392727 | 0.84 | MAPT (0.68) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL29435691 | 0.84 | MAPT (0.68) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL31006175 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL19021795 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL26641270 | 0.84 | MAPT (0.70) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL25204395 | 0.81 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL30484821 | 0.81 | MAPT (0.52) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL15174824 | 0.81 | MAPT (0.52) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383877-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| US-12122763-B2 | Substituted piperidines for androgen receptor degradation | UBIX THERAPEUTICS, INC. (KR) | 2024-10-22 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4186904-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | Ubix Therapeutics, Inc. (KR) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022019597-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | 주식회사 유빅스테라퓨틱스 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | MAPT 2978/4885ALDH1A1 550/4885LMNA 2801/4885 |
| US-20240383877-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, ESRRA | MAPT 4124/4885ALDH1A1 104/4885LMNA 3498/4885 |
| US-12122763-B2 | Substituted piperidines for androgen receptor degradation | AR, NR5A1, ESRRA | MAPT 4610/4885ALDH1A1 143/4885LMNA 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.